SynaptiCure careers
OUR STORY
For decades, patients and caregivers have experienced firsthand that only a select few ALS patients have access to the best clinics, testing and treatment options. We were told not to waste our time trying to understand our particular version of ALS but instead accept a care system and generic therapies that did nothing to change the outcome of the disease.
Like cancer before, a better way is now possible for all ALS patients. Thanks to advances in science, technology and computational analytics we are beginning to be able to identify and treat each patient’s unique disease. Synapticure was built by leading patient and caregiver advocates alongside leading ALS clinicians, biotech executives and telemedicine executives to bring the ALS care and treatment experience into the 21st century.
For decades, patients and caregivers have experienced firsthand that only a select few ALS patients have access to the best clinics, testing and treatment options. We were told not to waste our time trying to understand our particular version of ALS but instead accept a care system and generic therapies that did nothing to change the outcome of the disease.
Like cancer before, a better way is now possible for all ALS patients. Thanks to advances in science, technology and computational analytics we are beginning to be able to identify and treat each patient’s unique disease. Synapticure was built by leading patient and caregiver advocates alongside leading ALS clinicians, biotech executives and telemedicine executives to bring the ALS care and treatment experience into the 21st century.
Finance Director
Remote only • United States
$150k – $180k2 months ago
PETER WALLACH
Founder, stealth co • biotech investor • Worked at @Bain & Company
Valuation
$0
Funded over
1 round
Latest round